Baerveldt shunt lowers IOP

Article

Baerveldt shunts effectively lower IOP in eyes with anterior uveal melanoma (AUM) undergoing anterior segment irradiation.

Baerveldt shunts effectively lower IOP in eyes with anterior uveal melanoma (AUM) undergoing anterior segment irradiation.

An investigation, led by Dr Eamon Sharkawi, Hôpital Ophtalmique Jules-Gonin, Université de Lausanne, Switzerland, including 31 eyes with uncontrolled IOP. Each patient underwent anterior segment proton beam radiotherapy (PBRT) and Baerveldt shunt implantation.

Postoperative assessments were conducted on day 1, weeks 1, 3, 6, 9 and months 3, 6, 9 and 12 annually thereafter. IOP that was 21 mm Hg or less was defined as a surgical success, as well as 20% reduction from baseline.

Mean preoperative IOP was recorded at 3.10 mm Hg and mean IOP at the last visit was 15.0 mm Hg. The surgical success rate was 86% after using glaucoma medications. Of the eyes studied, four had minor postoperative complications but there were no local tumour recurrences, systemic metastases or no enucleations caused by ocular hypertension.

The abstract can be found in the British Journal of Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.